Guideline Summary for Chronic Hepatitis C Management

Initial Evaluation and Baseline Testing

• Confirm active infection and obtain a baseline viral load by performing quantitative HCV RNA testing before any therapy 1.
• Assess liver fibrosis non‑invasively (e.g., FIB‑4 or APRI) to identify cirrhosis, which determines treatment duration 1.
• Screen all patients for hepatitis B and HIV coinfection because co‑infection may modify therapeutic choices 1.
• Genotype testing is not required for treatment‑naïve patients without cirrhosis who will receive a pangenotypic regimen, but it is recommended for treatment‑experienced individuals 1, 2.

Preferred Pangenotypic Regimens (All Genotypes)

• Sofosbuvir / velpatasvir for 12 weeks is the standard option for most patients 2.
• Glecaprevir / pibrentasvir for 8 weeks (no cirrhosis) or 12 weeks (compensated cirrhosis) is an equally effective alternative 2.
• Sofosbuvir / velpatasvir / voxilaprevir is reserved for treatment‑experienced patients with cirrhosis 2.

Genotype‑Specific Regimens

Genotype 1a

Genotype 2

Genotype 3

Genotype 4

Counseling, Vaccination, and Prevention

• Advise complete alcohol abstinence; no safe level of alcohol exists for chronic HCV infection 1.
• Provide hepatitis A and B vaccination to all susceptible individuals 1.
• Offer pneumococcal vaccination to patients with cirrhosis 1.
• Educate patients on measures to prevent HCV transmission to others 1.

Monitoring and Treatment Success

• Assess sustained virologic response (SVR) by quantitative HCV RNA testing 12 weeks after the end of therapy; SVR denotes cure 1.

Special Populations

• HIV/HCV coinfection: Use the same DAA regimens, but carefully review drug‑drug interactions with antiretroviral therapy 1, 2.
• Decompensated cirrhosis (Child‑Pugh B/C): Management requires specialist oversight and modified regimens not covered in standard guidance 2.

Common Pitfalls to Avoid

• Do not delay therapy in patients with active substance use; adherent individuals achieve SVR rates comparable to others 1.
• Avoid unnecessary genotype testing in treatment‑naïve, non‑cirrhotic patients receiving pangenotypic therapy 1, 2.
• Perform NS5A resistance‑associated substitution testing in patients who have previously failed an NS5A inhibitor, as resistance guides retreatment choice 3, 4.

Hepatitis C Antiviral Regimens and Clinical Guidance

Fixed‑Dose Combination Products – Pangenotypic Regimens

Fixed‑Dose Combination Products – Genotype‑Specific Regimens

Individual Component Medications – NS5B Polymerase Inhibitors

Individual Component Medications – NS5A Inhibitors

Individual Component Medications – NS3/4A Protease Inhibitors (Older Generation)

Adjunctive Medications

Key Clinical Considerations – Treatment Selection

Special Population Considerations

Evidence‑Based Recommendations for Diagnosis, Treatment, and Follow‑Up of Chronic Hepatitis C

Initial Evaluation and Baseline Assessment

• Quantitative HCV RNA testing must be performed to confirm infection and document baseline viral load before any therapy is started. 18
• Liver fibrosis should be staged non‑invasively using FIB‑4 or APRI scores; identification of cirrhosis guides treatment duration and post‑treatment monitoring intensity. 18
• All individuals should be screened for hepatitis B and HIV coinfection because these conditions alter antiviral selection and require careful drug‑interaction management. 18
• Genotype testing is not required for treatment‑naïve, non‑cirrhotic patients who will receive a pangenotypic regimen, but it is required for patients with prior DAA failure or who are treatment‑experienced. 18

First‑Line Pangenotypic Regimens

Treatment‑Naïve Patients Without Cirrhosis

• Glecaprevir/pibrentasvir for 8 weeks (three tablets once daily) provides high cure rates across genotypes 1–6. [19][20]
• Sofosbuvir/velpatasvir for 12 weeks (single tablet once daily) provides comparable cure rates across genotypes 1–6. [19][20]

Treatment‑Naïve Patients With Compensated Cirrhosis

• Glecaprevir/pibrentasvir for 12 weeks is effective for compensated cirrhosis regardless of genotype. [19][20]
• Sofosbuvir/velpatasvir for 12 weeks is similarly effective for compensated cirrhosis. [19][20]
• In genotype 3 cirrhosis, adding ribavirin to sofosbuvir/velpatasvir or using the triple‑combination sofosbuvir/velpatasvir/voxilaprevir for 8 weeks can be considered. [19][20]

Genotype‑Specific Regimens (When a Pangenotypic Approach Is Not Preferred)

Genotype 1

• Ledipasvir/sofosbuvir for 12 weeks is highly effective in both treatment‑naïve and treatment‑experienced patients. 19
• Elbasvir/grazoprevir for 12 weeks is an alternative when no NS5A resistance‑associated substitutions are present. 19

Genotype 3 (Historically Difficult‑to‑Treat)

• Without cirrhosis: glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12 weeks. [19][20]
• With cirrhosis: sofosbuvir/velpatasvir + ribavirin for 12 weeks or sofosbuvir/velpatasvir/voxilaprevir for 8 weeks. [19][20]
• Treatment‑experienced: glecaprevir/pibrentasvir for 16 weeks or sofosbuvir/velpatasvir + ribavirin for 12 weeks. [19][20]

Genotype 4

• Options include ledipasvir/sofosbuvir 12 weeks, elbasvir/grazoprevir 12 weeks, or glecaprevir/pibrentasvir for 8–12 weeks depending on cirrhosis status. 19
• For patients with prior on‑treatment virologic failure, elbasvir/grazoprevir + ribavirin for 16 weeks is recommended. 19
• Ombitasvir/paritaprevir/ritonavir + ribavirin for 12 weeks achieved 97–100 % SVR in phase 3 trials (higher pill burden). 19

Retreatment After Direct‑Acting Antiviral (DAA) Failure

• Sofosbuvir/velpatasvir/voxilaprevir for 8–12 weeks is the preferred retreatment regimen for any genotype after prior DAA failure, achieving 96–99 % SVR in treatment‑experienced cirrhotic patients. 20
• In genotype 3 treatment‑experienced cirrhosis, either sofosbuvir/velpatasvir/voxilaprevir for 8 weeks or glecaprevir/pibrentasvir for 16 weeks can be used. [19][20]

Special Populations

HIV/HCV Coinfection

• The same DAA regimens used in HIV‑negative individuals are recommended for HIV‑coinfected patients. 18

Active Substance Use

• Initiation of antiviral therapy should not be delayed in patients with ongoing injection drug use or alcohol consumption; adherence yields SVR rates comparable to other groups. 18
• Ongoing alcohol use is not a contraindication to therapy, though counseling for abstinence remains essential. 18

Counseling, Vaccination, and Prevention

• Complete alcohol abstinence is advised for all chronic HCV patients because any alcohol intake accelerates fibrosis progression and increases hepatocellular carcinoma risk. 18
• Hepatitis A and B vaccinations should be offered to all susceptible individuals. 18
• Pneumococcal vaccination is recommended for all patients with cirrhosis. 18
• Patients should be educated on HCV transmission prevention (avoid sharing needles, razors, toothbrushes; use barrier protection during sexual activity when appropriate). 18

Monitoring and Follow‑Up

• Sustained virologic response (SVR) is confirmed by a quantitative HCV RNA test performed 12 weeks after completing therapy; undetectable RNA defines cure.
• Patients with cirrhosis require ongoing hepatocellular carcinoma surveillance with ultrasound ± AFP every 6 months, even after achieving SVR. 18
• Endoscopic screening for gastroesophageal varices should be performed in cirrhotic patients. 18
• Avoid hepatotoxic agents (e.g., acetaminophen >2 g/day, certain herbal supplements) and nephrotoxic drugs (e.g., NSAIDs) in cirrhotic individuals. 18

Common Pitfalls to Avoid

• Do not perform unnecessary genotype testing in treatment‑naïve, non‑cirrhotic patients receiving pangenotypic therapy, as it delays treatment and adds cost. 18
• Do not withhold antiviral therapy from patients with active substance use, psychiatric comorbidities, or ongoing alcohol consumption if they are adherent. 18

Guideline Summary for Chronic Hepatitis C Management

First‑Line Pan‑Genotypic Regimens

• Sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8 weeks (in patients without cirrhosis) achieve sustained virologic response (SVR) rates > 95 % across all HCV genotypes. 21
• In treatment‑naïve adults without cirrhosis, glecaprevir/pibrentasvir for 8 weeks is preferred because it provides the shortest effective course while covering genotypes 1–6. 21
• Sofosbuvir/velpatasvir for 12 weeks is an equally effective once‑daily alternative for treatment‑naïve adults without cirrhosis. 22
• In treatment‑naïve adults with compensated cirrhosis (Child‑Pugh A), glecaprevir/pibrentasvir for 12 weeks maintains high cure rates. 22
• Sofosbuvir/velpatasvir for 12 weeks remains effective regardless of compensated cirrhosis status. 22
• For genotype 3 infection with compensated cirrhosis, intensified therapy is required; any of the following regimens achieve high SVR: (1) sofosbuvir/velpatasvir + weight‑based ribavirin for 12 weeks, (2) sofosbuvir/velpatasvir/voxilaprevir for 12 weeks, or (3) glecaprevir/pibrentasvir for 12 weeks. 21

Genotype‑Specific Regimens (When Pan‑Genotypic Approach Is Not Used)

Genotype 1

• Ledipasvir/sofosbuvir for 12 weeks yields SVR > 95 % in treatment‑naïve adults without cirrhosis. 22
• The same regimen can be shortened to 8 weeks in patients without cirrhosis, without HIV coinfection, and with baseline HCV RNA < 6 million IU/mL. 22
• Elbasvir/grazoprevir for 12 weeks is effective when no NS5A resistance‑associated substitutions are present. 22
• Glecaprevir/pibrentasvir for 8 weeks is effective in treatment‑experienced adults without cirrhosis. 21

Genotype 2

• Sofosbuvir/velpatasvir for 12 weeks is effective in treatment‑naïve adults without cirrhosis. 21
• Sofosbuvir + ribavirin for 12 weeks achieved 97–98 % SVR in phase‑3 trials. 22

Genotype 3 (Historically Difficult‑to‑Treat)

• Glecaprevir/pibrentasvir for 8 weeks is effective in treatment‑naïve adults without cirrhosis. 21
• In compensated cirrhosis, any of the following regimens achieve high SVR: (1) sofosbuvir/velpatasvir + weight‑based ribavirin for 12 weeks, (2) sofosbuvir/velpatasvir/voxilaprevir for 12 weeks, or (3) glecaprevir/pibrentasvir for 12 weeks. 21
• If the NS5A Y93H resistance mutation is present, use sofosbuvir/velpatasvir + ribavirin or sofosbuvir/velpatasvir/voxilaprevir; if absent, sofosbuvir/velpatasvir alone for 12 weeks is sufficient. 21

Genotype 4

• Ledipasvir/sofosbuvir for 12 weeks is effective in both treatment‑naïve and treatment‑experienced adults without cirrhosis. 23
• Glecaprevir/pibrentasvir for 8 weeks is an alternative pan‑genotypic option in patients without cirrhosis. 21

Genotypes 5 and 6

• Sofosbuvir/velpatasvir for 12 weeks is effective across genotypes 5 and 6. 21
• Ledipasvir/sofosbuvir for 12 weeks is also effective for genotypes 5 and 6. 23
• Glecaprevir/pibrentasvir for 8 weeks (no cirrhosis) or 12 weeks (compensated cirrhosis) provides a pan‑genotypic option. 21

Special Populations

HIV/HCV Coinfection

• The same direct‑acting antiviral (DAA) regimens used in HIV‑negative patients are recommended for HIV‑coinfected individuals, with careful review of drug‑drug interactions. 21

Pediatric Patients (≥ 3 Years)

• Glecaprevir/pibrentasvir for 8 weeks is approved for adolescents ≥ 12 years or ≥ 45 kg, for any genotype, with or without compensated cirrhosis. 23
• Ledipasvir/sofosbuvir (weight‑based dosing) for 12 weeks is approved for children ≥ 3 years with genotypes 1, 4, 5, or 6, with or without compensated cirrhosis. 23
• All children with chronic HCV should be treated regardless of disease severity to prevent long‑term complications and support elimination goals. 23

Drug‑Interaction and Safety Considerations

• Concomitant use of carbamazepine, efavirenz, or St. John’s wort with glecaprevir/pibrentasvir should be avoided because these agents markedly reduce antiviral concentrations. 23
• In genotype 3 infection with cirrhosis, a standard 12‑week course of sofosbuvir/velpatasvir alone (without ribavirin or a third agent) should be avoided due to lower response rates. 21

Retreatment After Prior DAA Failure

• For genotype 3‑infected patients who have previously failed a DAA regimen and have compensated cirrhosis, either sofosbuvir/velpatasvir/voxilaprevir for 8 weeks or glecaprevir/pibrentasvir for 16 weeks provides high SVR rates. 21

Management of Reactive Hepatitis C in Nursing‑Home Residents

Diagnostic Confirmation

• Quantitative HCV RNA PCR testing should be performed immediately to confirm chronic active infection, because a positive anti‑HCV antibody alone cannot distinguish active infection from cleared disease. 24, 25
• A positive HCV RNA result indicates chronic hepatitis C that requires antiviral treatment. 24, 25
• If the initial HCV RNA test is negative, repeat testing after 3 months is recommended to rule out transient undetectable viremia and confirm resolved infection. 24

Baseline Assessment Before Therapy

• Calculate the FIB‑4 score (age, AST, ALT, platelet count); a score > 3.25 suggests advanced fibrosis and guides treatment duration. 25, 26
• Screen for hepatitis B (HBsAg, anti‑HBs, anti‑HBc) and HIV, as coinfection influences therapeutic choices and monitoring. 25
• Obtain baseline laboratory studies including a complete blood count, comprehensive metabolic panel with estimated glomerular filtration rate, INR, and liver function tests. 26
• Genotype testing is not required for treatment‑naïve patients without cirrhosis who will receive a pangenotypic direct‑acting antiviral (DAA) regimen. 26

First‑Line Pangenotypic Regimens

Patients Without Cirrhosis (FIB‑4 ≤ 3.25)

• Glecaprevir/pibrentasvir for 8 weeks (three tablets once daily) is the preferred short regimen, achieving >95 % sustained virologic response (SVR) across all genotypes. 26
• Sofosbuvir/velpatasvir for 12 weeks (one tablet once daily) provides an equally effective alternative. 26

Patients With Compensated Cirrhosis (FIB‑4 > 3.25 or other evidence)

• Glecaprevir/pibrentasvir for 12 weeks or Sofosbuvir/velpatasvir for 12 weeks are both recommended. 26

On‑Treatment Monitoring

• Routine laboratory monitoring is unnecessary during DAA therapy unless the patient develops side effects or adherence concerns. 26
• For patients receiving diabetes medications, monitor for symptomatic hypoglycemia and adjust glucose‑lowering agents as needed. 26
• For patients on warfarin, check INR periodically to detect sub‑therapeutic anticoagulation and modify the warfarin dose if required. 26
• Clinical visits (in‑person or telemedicine) every 2–4 weeks provide support, assess adherence, and allow early detection of adverse events. 26

Post‑Treatment Assessment

• Quantitative HCV RNA testing should be performed 12 weeks after completing therapy to confirm SVR, which denotes virologic cure. 24, 25, 26
• If SVR is achieved and the patient has no cirrhosis, no further liver‑specific follow‑up is necessary. 26
• In patients with cirrhosis, continue hepatocellular carcinoma (HCC) surveillance with abdominal ultrasound ± alpha‑fetoprotein every 6 months indefinitely, even after SVR. 26

Counseling, Prevention, and Facility Practices

• Educate nursing‑home staff on HCV transmission prevention measures, such as avoiding shared razors, nail clippers, or any items that may contact blood. 25

Common Pitfalls to Avoid

• Do not delay treatment while awaiting genotype results in treatment‑naïve, non‑cirrhotic patients receiving a pangenotypic regimen; this adds cost and postpones cure. 26
• Do not perform unnecessary on‑treatment laboratory monitoring in stable patients who are not on diabetes agents or warfarin, as it increases cost without improving outcomes. 26
• Do not discontinue HCC surveillance in cirrhotic patients after achieving SVR; the risk of HCC persists, albeit at a reduced level. 26

Direct‑Acting Antiviral Regimens for Hepatitis C – Evidence‑Based Recommendations

1. Core Antiviral Drug Classes

• Sofosbuvir is the backbone nucleotide polymerase inhibitor that blocks HCV RNA replication and underpins most modern regimens. 27
• NS5A inhibitors (ledipasvir, velpatasvir, daclatasvir, elbasvir, ombitasvir, pibrentasvir) inhibit the NS5A protein essential for viral replication and assembly. 27
• When combined with other DAA classes, NS5A inhibitors provide pangenotypic coverage across genotypes 1‑6. 28
• NS3/4A protease inhibitors (grazoprevir, paritaprevir, glecaprevir, voxilaprevir) block the NS3/4A protease required for viral polyprotein processing. 27
• Protease inhibitors are absolutely contraindicated in decompensated cirrhosis (Child‑Pugh B or C) because of markedly increased drug exposure and hepatotoxicity risk. 28

2. Fixed‑Dose Combination Regimens

2.1 Pangenotypic Combinations (genotypes 1‑6)

• Sofosbuvir + velpatasvir (Epclusa) – once‑daily for 12 weeks; achieves >95 % sustained virologic response (SVR) across all genotypes. 29
• Glecaprevir + pibrentasvir (Mavyret) – three tablets once‑daily; 8 weeks in patients without cirrhosis, 12 weeks in those with compensated cirrhosis; provides pangenotypic efficacy. 27
• Sofosbuvir + velpatasvir + voxilaprevir (Vosevi) – triple‑combination reserved for patients who failed prior DAA therapy; administered for 8‑12 weeks. 29

2.2 Genotype‑Specific Combinations

• Ledipasvir + sofosbuvir (Harvoni) – single‑tablet regimen primarily for genotypes 1, 4, 5, 6; duration 8‑12 weeks depending on baseline viral load and cirrhosis status. 27
• Elbasvir + grazoprevir (Zepatier) – once‑daily tablet for genotypes 1 and 4; treatment length 12‑16 weeks based on resistance testing. 27
• Ombitasvir + paritaprevir + ritonavir (± dasabuvir) – multi‑tablet regimen for genotypes 1 and 4; always combined with ribavirin. 27

3. Adjunctive Medications

• Weight‑based ribavirin (1,000–1,200 mg daily) is added to DAA regimens in specific situations: genotype 3 with cirrhosis, treatment‑experienced patients with cirrhosis, decompensated cirrhosis, or presence of NS5A resistance mutations. 27
• Adding ribavirin to daclatasvir + sofosbuvir improves SVR in cirrhotic genotype 4 patients from ~84 % to ~93 %. 27
• In genotype 3 cirrhosis, ribavirin combined with sofosbuvir + velpatasvir raises SVR to >95 %. 29

4. Treatment Selection for Specific Patient Populations

• Treatment‑naïve patients with compensated cirrhosis: either glecaprevir + pibrentasvir for 12 weeks or sofosbuvir + velpatasvir for 12 weeks. 29
• Genotype 3 with cirrhosis: options include (a) sofosbuvir + velpatasvir + ribavirin for 12 weeks, (b) sofosbuvir + velpatasvir + voxilaprevir for 8 weeks, or (c) glecaprevir + pibrentasvir for 12 weeks. 29
• DAA‑experienced patients: sofosbuvir + velpatasvir + voxilaprevir for 8‑12 weeks or glecaprevir + pibrentasvir for 16 weeks (genotype 3). 29
• Decompensated cirrhosis (Child‑Pugh B/C): use only NS5A‑based combinations without protease inhibitors; sofosbuvir + velpatasvir ± ribavirin is the regimen of choice. 28

5. Special Clinical Considerations

• HIV coinfection: the same DAA regimens are applicable, but careful antiretroviral drug‑interaction review is required; daclatasvir dosing is adjusted to 30 mg with ritonavir‑boosted protease inhibitors and 90 mg with efavirenz. 27

• Severe renal impairment (eGFR < 30 mL/min): avoid sofosbuvir‑based regimens; preferred alternatives are elbasvir + grazoprevir or ombitasvir + paritaprevir + ritonavir. [no citation – omitted]

• Drug‑interaction cautions: avoid concomitant use of carbamazepine, efavirenz, phenytoin, rifampin, or St. John’s wort with any DAA regimen due to significant reductions in antiviral concentrations. [no citation – omitted]

Management of Thrombocytopenia in Patients Receiving Epclusa (Sofosbuvir/Velpatasvir)

Treatment Recommendations for Patients with No Cirrhosis or Compensated Cirrhosis (Child‑Pugh A)

• Standard 12‑week Sofosbuvir/Velpatasvir therapy is recommended for all HCV genotypes in both treatment‑naïve and treatment‑experienced patients with compensated cirrhosis, irrespective of baseline platelet count. No dose adjustment or treatment modification is required for thrombocytopenia, and platelet transfusions are not indicated solely to start therapy. [30][31]

Treatment Recommendations for Patients with Decompensated Cirrhosis (Child‑Pugh B or C)

• Sofosbuvir/Velpatasvir remains the preferred regimen in decompensated cirrhosis, but patients should be monitored closely. Protease‑inhibitor‑containing regimens are absolutely contraindicated because of increased drug exposure and hepatotoxicity risk. 31
• In the ASTRAL‑4 trial, patients with Child‑Pugh B decompensated cirrhosis achieved high sustained virologic response (SVR) rates when treated with Sofosbuvir/Velpatasvir ± ribavirin. 31
• A Phase 2 study reported a 78.1 % SVR12 rate (100 % per‑protocol) for decompensated cirrhosis patients receiving Sofosbuvir/Velpatasvir + ribavirin, with all Grade 3‑4 adverse events judged unrelated to the antiviral regimen. 31

Role of Ribavirin in Thrombocytopenic Patients

• Ribavirin should be avoided or used only with extreme caution in patients with thrombocytopenia. It is added only for specific indications: genotype 3 with cirrhosis, treatment‑experienced patients with cirrhosis, or presence of NS5A resistance‑associated substitutions. [32][31]
• Weight‑based ribavirin dosing (≈1 g daily for patients < 75 kg; ≈1.2 g for ≥ 75 kg) can exacerbate anemia, which may indirectly worsen platelet management. 32
• In decompensated cirrhosis, ribavirin is contraindicated or should be used only with extreme caution because of poor tolerability. 31

Monitoring Strategy During Epclusa Therapy

• Routine laboratory monitoring (e.g., complete blood count) is not required for stable patients without comorbidities. Monitoring is reserved for those on diabetes medications (to detect hypoglycemia) or warfarin (to check INR). [@—] (no citation needed; omitted because no cited source)
• Clinical visits every 2–4 weeks—either in‑person or via telemedicine—provide adherence support and allow early detection of adverse events. [@—] (no citation needed; omitted because no cited source)

Expected Hematologic Outcomes After HCV Eradication

• Successful HCV eradication (SVR) is consistently associated with a rise in platelet count, confirming that thrombocytopenia in chronic HCV is largely disease‑related rather than drug‑induced. [@—] (no citation needed; omitted because no cited source)

Common Clinical Pitfalls to Avoid

• Do not delay or withhold Sofosbuvir/Velpatasvir therapy solely because of low platelet counts; the regimen does not cause clinically significant platelet reduction. [30][31]
• Do not add ribavirin routinely in thrombocytopenic patients unless the specific indications (genotype 3 cirrhosis, prior treatment failure, NS5A resistance) are present. 31
• Do not perform unnecessary on‑treatment laboratory monitoring in stable patients without diabetes or anticoagulation, as it adds cost without improving outcomes. [@—] (no citation needed; omitted because no cited source)
• Do not use protease‑inhibitor‑containing regimens in decompensated cirrhosis, given the absolute contraindication due to hepatotoxicity risk. 31